Market Place
Sourcing Support
Relmada discontinues Ph3 Trials For REL-1017 Treatment Studies
10 Dec 2024 //
PRESS RELEASE
Relmada To Present At Jefferies London Healthcare Conference
19 Nov 2024 //
GLOBENEWSWIRE
Relmada Doses 1st Patient with REL-P11 for Metabolic Disease
14 Nov 2024 //
GLOBENEWSWIRE
Relmada Therapeutics Reports Q3 2024 Financial Results & Update
07 Nov 2024 //
GLOBENEWSWIRE
Relmada Reports Q3 2024 Financials & Business Update
07 Nov 2024 //
PR NEWSWIRE
Relmada Therapeutics to Report Q3 2024 Results on Nov 7
04 Nov 2024 //
GLOBENEWSWIRE
Relmada Therapeutics Reports Q2 2024 Results And Business Update
07 Aug 2024 //
GLOBENEWSWIRE
Relmada Therapeutics Reports Q2 2024 Results And Provides Update
07 Aug 2024 //
PR NEWSWIRE
Relmada Therapeutics To Report Q2 2024 Results On August 7
05 Aug 2024 //
GLOBENEWSWIRE
Relmada Therapeutics Provides Corporate Update
04 Jan 2024 //
PR NEWSWIRE
Relmada Therapeutics to Present New Preclinical Data on its Psilocybin Program
11 Oct 2023 //
PR NEWSWIRE
Relmada Therapeutics to Present Data from its REL-1017 and Psilocybin Programs
06 Oct 2023 //
PR NEWSWIRE
Relmada’s major depression drug shows PhIII promise in a fresh batch of patients
21 Sep 2023 //
ENDPTS
Relmada to Participate in the 2023 Jefferies Global Healthcare Conference
02 Jun 2023 //
PR NEWSWIRE
Relmada Therapeutics to Report 1Q 2023 FYR and Host Conference Call
08 May 2023 //
PR NEWSWIRE
After phase 3 flops, Relmada plots depression drug comeback
25 Mar 2023 //
FIERCE BIOTECH
Relmada Therapeutics to Report Fourth Quarter & Full-Year 2022 Financial Results
17 Mar 2023 //
PR NEWSWIRE
Relmada sinks further as depression drug fails second large trial
09 Dec 2022 //
BIOPHARMADIVE
Relmada`s depression drug fails late-stage trial; shares crash
14 Oct 2022 //
REUTERS
Relmada Announces Top-line Results from Phase 3 RELIANCE III Trial for REL-1017
13 Oct 2022 //
RELMADA
Relmada Therapeutics to Participate in the Goldman Sachs Conference
07 Jun 2022 //
PRNEWSWIRE
Relmada Therapeutics to Present Data at the ASCP 2022
25 May 2022 //
PRNEWSWIRE
Relmada Therapeutics Announces Publication of REL-1017 Preclinical Data
29 Apr 2022 //
PRNEWSWIRE
Relmada Tx to Present Data at the Ketamine & Related Compounds Conference 2022
04 Apr 2022 //
PRNEWSWIRE
Relmada Therapeutics to Participate in the 11th Annual SVB Leerink Conference
10 Feb 2022 //
PRNEWSWIRE
Relmada to Publish REL-1017 Phase 2 Study Results
22 Dec 2021 //
PRNEWSWIRE
Relmada Therapeutics Announces Proposed Public Offering of Common Stock
08 Dec 2021 //
RELMADA
Relmada Therapeutics to Present Data at the Neuroscience Education
29 Oct 2021 //
RELMADA
Relmada to Report Second Quarter 2021 Financial Results
05 Aug 2021 //
PRNEWSWIRE
Relmada Therapeutics to Report Second Quarter 2021 Financial Results
05 Aug 2021 //
PRNEWSWIRE
Relmada to explore psychedelic avenue in pursuit of depression treatment
20 Jul 2021 //
ENDPTS
Relmada to Present Data at the College on Problems of Drug Dependence
15 Jun 2021 //
PRNEWSWIRE
Relmada Therapeutics Takes Part in Goldman Sachs Global Healthcare Conference
07 Jun 2021 //
PRNEWSWIRE
Relmada Therapeutics Announces Oral Poster Presentation on REL-1017
26 May 2021 //
PRNEWSWIRE
Relmada Provides Corporate Update & Reports Q1 2021 Financial Results
12 May 2021 //
GLOBENEWSWIRE
Relmada Announces Poster Presentations at the 2021 Society
29 Apr 2021 //
PRNEWSWIRE
Relmada Therapeutics Announces Participation in the 7th Annual Truist Securities
28 Apr 2021 //
PRNEWSWIRE
Relmada Announces Poster Presentation at the American Society
27 Apr 2021 //
PRNEWSWIRE
Relmada Announces Initiation of Second Pivotal Phase 3 Study of REL-1017
01 Apr 2021 //
PRNEWSWIRE
Relmada Announces Initiation of Phase 3 Program for REL-1017
07 Dec 2020 //
PRNEWSWIRE
Relmada Therapeutics Announces Initiation of Phase 3 Program for REL-1017
07 Dec 2020 //
PRNEWSWIRE
Relmada Announces Notice of Allowance for Patent in Canada Covering REL-1017
23 Jun 2020 //
PRNEWSWIRE
Relmada to Present at the Jefferies 2020 Virtual Healthcare Conference
29 May 2020 //
PRNEWSWIRE
Relmada Announces Outcome of End-of-Phase 2 Meeting with FDA for REL-1017
27 May 2020 //
PRNEWSWIRE
Relmada`s Strengthens Scientific Leadership Team with the Appointment
24 Mar 2020 //
PR NEWSWIRE
Relmada Therapeutics Appoints CNS Specialist Thomas C. Wessel
09 Mar 2020 //
PR NEWSWIRE
Relmada Therapeutics Announces Pricing of Public Offering of Common Stock
03 Dec 2019 //
PR NEWSWIRE
Relmada Therapeutics Announces Completion of Dosing with REL-1017
29 Jul 2019 //
PR NEWSWIRE
